On Wednesday, CommVault Systems, Inc. (NASDAQ:CVLT)’s shares gained 5.62%, and closed at $46.60, as CommVault will release the Corporation’s financial results for its fiscal fourth quarter and year ended March 31, 2015, on Tuesday, May 5, 2015, followed by a webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
CommVault Systems, Inc., together with its auxiliaries, provides data and information administration software applications and related services primarily in North America, Europe, Australia, and Asia. The corporation develops, markets, and sells a suite of software applications and services under the Simpana brand.
DepoMed Inc. (NASDAQ:DEPO)’s shares jumped 5.53%, and settled at $24.44, during the last trading session on Wednesday, as on April 2, DepoMed declared that it has closed the attainment of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise comprises: NUCYNTA® ER (tapentadol) extended release tablets indicated for the administration of pain, counting neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA® (tapentadol), an immediate release version of tapentadol, for administration of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. NUCYNTA is now the flagship asset in Depomed’s growing portfolio of pain and neurology specialty pharmaceuticals.
Transition Highlights:
- Depomed will start shipping NUCYNTA the week of April 6, reflecting a price adjustment made after closing the deal
- Quintiles, the contract sales organization that promoted the NUCYNTA franchise for Janssen, will continue to support these products for Depomed from now until re-launch in June
- Depomed anticipates its expanded sales force supporting NUCYNTA, Gralise, Cambia and Zipsor to be fully deployed at re-launch
- Depomed will introduce new product positioning and marketing support focusing on the uniqueness of the molecule and its dual mechanism of action (MOA)
- The $575 million loan to complete financing of the transaction closed as predictable, with no dilution to shareholders
- The corporation plans to update 2015 guidance inclusive of NUCYNTA sales as part of the first quarter financial report in May.
Depomed, Inc., a specialty pharmaceutical corporation, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
At the end of Wednesday’s trade, GOL Linhas Aéreas Inteligentes S.A. (NYSE:GOL)’s shares climbed 5.51%, and closed at $2.68, after the largest low-cost and best-fare airline in Latin America, informed its shareholders and the market in general that it was the leader in punctuality in the first quarter of 2015, with an index of 94.13%, according to data from Infraero (Brazilian Airport Infrastructure Corporation) on the domestic market. In March, the Corporation’s index reached 96.72%, with more than 23,000 domestic flights in the period.
This result reinforces GOL’s commitment to punctuality and customer satisfaction. For a year, the Corporation has been informing passengers about the punctuality of their flights through voice messages inside the aircraft and has been investing in other fronts to ensure greater speed and convenience during the trip. These comprise services accessible via mobile phone, such as flight status consultation, ticket purchases, check-in, seat selection, ticket anticipation and cancellation.
Gol Linhas Aéreas Inteligentes S.A. provides regular and non-regular air transportation services for passengers, cargoes, and mailbags in Brazil and internationally. It operates in two segments, Flight Transportation and Smiles Loyalty Program.
Coronado Biosciences, Inc. (NASDAQ:CNDO), ended its Wednesday’s trading session with 5.48% gain, and closed at $4.04, as on April 2, a biopharmaceutical corporation, formed a new partner corporation, DiaVax Biosciences, to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV), a ordinary virus that affects people of all ages. According to the U.S. Centers for Disease Control and Prevention (CDC), while CMV is typically asymptomatic in healthy individuals, it can cause serious, often life-threatening disease in those with weakened or uneducated immune systems (counting developing fetuses exposed to the virus in utero).
The licensed immunotherapies were developed in the laboratory of Don J. Diamond, Ph.D., Chair of the Department of Experimental Therapeutics at City of Hope National Medical Center in Duarte, California. Dr. Diamond will chair the Scientific Advisory Board of DiaVax. Under the contract with City of Hope, DiaVax secured worldwide rights to two T-cell immunotherapeutic vaccines for controlling CMV in allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. Known as Triplex and PepVax, the programs are predictable to enter Phase II clinical studies later this year and are supported by grants from the National Cancer Institute. In connection with the licensing of Triplex and PepVax, DiaVax further reached an option contract with City of Hope for exclusive worldwide rights to Pentamer, a universal immunotherapeutic vaccine being developed for the prevention of CMV transmission in utero. If DiaVax exercises its option, and successfully develops and commercializes PepVax, Triplex and Pentamer, City of Hope could receive in excess of $100MM in upfront, milestone and other payments.
Coronado Biosciences, Inc., a biopharmaceutical corporation, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development comprise Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
